◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › E › EVO

Evotec SE ADR (EVO) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-25

Evotec SE ADR (EVO) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Hamburg, Germany with about 4,461 employees. Its market capitalization is roughly $551 million. In the fiscal year ended 2025-12-31, EVO reported €757M in revenue and (€99M) in net income.

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.

Interactive charts & full statements → Open the EVO valuation workbench →

EVO Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	€722M	€757M	€797M	€781M	€751M	€618M	€501M	€446M	€375M	€258M	€165M	€128M	€89M	€86M	€87M	€80M	€55M	€43M	€40M	€33M	€67M
Gross Profit	€75M	€63M	€115M	€175M	€174M	€152M	€126M	€133M	€112M	€83M	€59M	€38M	€29M	€31M	€31M	€35M	€24M	€18M	€18M	€8M	€23M
Gross Margin %	10.4%	8.3%	14.4%	22.4%	23.2%	24.5%	25.1%	29.8%	29.8%	32.0%	35.6%	29.8%	32.8%	36.3%	35.5%	43.7%	44.1%	43.2%	44.5%	24.4%	34.1%
Operating Income (EBIT)	(€116M)	(€135M)	(€143M)	(€107M)	€21M	€41M	€49M	€63M	€77M	€37M	€31M	€12M	(€6M)	(€21M)	(€3M)	€5M	€2M	(€42M)	(€73M)	(€58M)	(€37M)
Operating Margin %	-16.0%	-17.9%	-17.9%	-13.7%	2.8%	6.6%	9.7%	14.0%	20.6%	14.5%	19.1%	9.1%	-7.1%	-24.8%	-3.7%	6.5%	3.1%	-99.1%	-184.8%	-176.7%	-54.6%
Net Income	(€200M)	(€99M)	(€196M)	(€84M)	(€176M)	€216M	€6M	€38M	€84M	€24M	€28M	€17M	(€7M)	(€25M)	€2M	€7M	€3M	(€45M)	(€78M)	(€11M)	(€32M)
Net Margin %	-27.7%	-13.1%	-24.6%	-10.7%	-23.4%	34.9%	1.2%	8.6%	22.4%	9.4%	16.7%	12.9%	-7.8%	-29.6%	2.8%	8.4%	5.9%	-106.6%	-197.6%	-33.9%	-48.2%
EBITDA	—	(€14M)	(€81M)	(€7M)	(€58M)	€317M	€90M	€87M	€106M	€35M	€46M	€25M	€5M	(€14M)	€5M	€14M	€9M	(€40M)	(€70M)	(€36M)	(€22M)
Earnings Per Share (EPS)	€-0.52	€-0.28	€-0.55	€-0.47	€-0.50	€0.65	€0.02	€0.13	€0.29	€0.08	€0.10	€0.06	€-0.03	€-0.10	€0.01	€0.03	€0.01	€-0.21	€-0.41	€-0.08	€-0.55
Shares Outstanding (M)	356M	355M	355M	177M	353M	333M	308M	299M	295M	290M	265M	275M	263M	242M	235M	232M	218M	214M	190M	144M	59M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EVO Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	€146M	€159M	€253M	€164M	€171M	€200M	€221M	€185M
Gross Profit	(€2M)	(€2M)	€78M	€0M	€9M	€27M	€46M	€18M
Gross Margin %	-1.1%	-1.0%	31.0%	-0.0%	5.0%	13.6%	20.8%	9.9%
Operating Income (EBIT)	(€52M)	(€56M)	€37M	(€45M)	(€28M)	(€20M)	€8M	(€26M)
Operating Margin %	-35.6%	-35.4%	14.7%	-27.2%	-16.2%	-10.0%	3.7%	-14.3%
Net Income	(€47M)	(€124M)	€15M	(€43M)	(€43M)	(€32M)	(€41M)	(€40M)
Net Margin %	-32.5%	-77.8%	5.8%	-26.3%	-25.4%	-15.8%	-18.5%	-21.4%
EBITDA	(€27M)	(€97M)	—	(€18M)	(€3M)	(€27M)	—	(€20M)
Earnings Per Share (EPS)	€-0.13	€-0.35	€0.08	€-0.12	€-0.12	€-0.09	€-0.23	€-0.11
Shares Outstanding (M)	356M	355M	177M	355M	355M	355M	178M	355M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EVO Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	(€116M)	(€9M)	€18M	€34M	€206M	€122M	€45M	€42M	€156M	€11M	€67M	€16M	(€4M)	€7M	€12M	€10M	€1M	(€22M)	(€41M)	(€32M)	(€9M)
Capital Expenditures (CapEx)	€50M	€70M	€132M	€216M	€181M	€119M	€99M	€32M	€28M	€18M	€10M	€11M	€5M	€5M	€10M	€8M	€2M	€2M	€4M	€4M	€3M
Free Cash Flow (FCF)	(€167M)	(€79M)	(€114M)	(€182M)	€24M	€3M	(€54M)	€10M	€128M	(€7M)	€57M	€4M	(€9M)	€1M	€2M	€2M	(€2M)	(€24M)	(€45M)	(€36M)	(€12M)
FCF Margin %	-23.1%	-10.4%	-14.3%	-23.3%	3.2%	0.5%	-10.8%	2.3%	34.2%	-2.6%	34.8%	3.2%	-10.1%	1.7%	2.0%	2.5%	-2.8%	-56.4%	-113.1%	-109.5%	-17.5%
Dividends Paid	€0M	€0M	€0M	€0M	€0M	€0M	—	—	—	€2M	€2M	€1M	€2M	€0M	—	—	€0M	€4M	—	€6M	€7M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EVO Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	(€110M)	(€2M)	€64M	(€68M)	€27M	(€32M)	€74M	€43M
Capital Expenditures (CapEx)	€9M	€4M	€16M	€21M	€24M	€22M	€25M	€28M
Free Cash Flow (FCF)	(€120M)	(€6M)	€48M	(€89M)	€3M	(€54M)	€49M	€14M
FCF Margin %	-82.0%	-4.0%	19.0%	-54.3%	1.6%	-26.8%	22.2%	7.7%

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EVO Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	€1.6B	€1.8B	€1.9B	€2.3B	€2.3B	€2.2B	€1.8B	€1.4B	€772M	€667M	€351M	€289M	€225M	€227M	€225M	€218M	€192M	€147M	€183M	€208M	€206M
Cash & Cash Equivalents	€348M	€418M	€306M	€511M	€401M	€699M	€517M	€311M	€109M	€67M	€84M	€44M	€49M	€46M	€39M	€18M	€21M	€33M	€55M	€38M	€79M
Total Liabilities	€908M	€965M	€960M	€1.2B	€1.1B	€857M	€951M	€844M	€347M	€336M	€137M	€101M	€66M	€68M	€73M	€71M	€59M	€35M	€33M	€37M	€68M
Total Debt (Short + Long-Term)	€476M	€448M	€444M	€456M	€345M	€377M	€368M	€348M	€112M	€189M	€22M	€6M	€13M	€17M	€13M	€13M	€9M	€10M	€3M	€2M	€4M
Total Shareholders' Equity	€666M	€813M	€953M	€1.1B	€1.2B	€1.4B	€886M	€535M	€424M	€331M	€213M	€186M	€158M	€159M	€153M	€147M	€132M	€111M	€150M	€171M	€137M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EVO viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

CRON · Cronos Group Inc — $1 billion
HROW · Harrow Health Inc — $1 billion
COLL · Collegium Pharmaceutical Inc — $773 million
IRWD · Ironwood Pharmaceuticals Inc — $578 million
AQST · Aquestive Therapeutics Inc — $487 million
EOLS · Evolus Inc — $487 million
TKNO · Alpha Teknova Inc — $454 million
KMDA · Kamada — $444 million

← EVNT All “E” companies EVOE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.